Analysis of CD117,DOG-1,CD34 and Ki67 expression levels,clinical significance and prognostic influencing factors in patients with inter-mediate-and high-risk gastrointestinal stromal tumors
Objective To investigate the expression level,clinical significance and prognostic factors of CD117,DOG-1,CD34 and Ki67 in gastrointestinal stromal tumors(GIST).Methods A retrospective study was conducted in 82 patients with intermediate and high-risk gastrointesti-nal stromal tumors from January 2015 to January 2018 admitted to our hospital.CD34,DOG-1,CD117 and Ki67 immunohistochemical markers were detected,and the general condition,pathological features,histological manifestations,immunohistochemical results,overall survival(OS)and recur-rence-free survival of 1,3 and 5 years were analyzed,and to study the influencing factors of OS and RFS in patients for 5 years.Results The positive rate of CD117,DOG-1 and Ki67 were 95.12%(78/82),96.34%(79/82)and 93.90%(77/82),respectively,which were significantly higher than that of D34 75.61%(62/82),and the difference was statistically significant(P＜0.05).The 1-,3-,and 5-year OS was 0%(0/82),3.66%(3/82),and 12.20%(10/82),and the 1-,3-,and 5-year RFS was 2.44%(2/82),28.05%(23/82),and 76.83%(63/82),respectively.Univariate prognostic analysis showed that there were significant differences in nuclear fission number,sex and OS(P＜0.05),age,targeted medication,rupture,tumor loca-tion,risk,Ki67 index,cell morphology,OS and RFS were statistically significant(P＜0.05),and the differences between the indices of immunohisto-chemical proteins and OS and RFS were not significant(P＞0.05).Conclusion Immunohistochemical markers are indicators for the diagnosis of GIST,and the number of nuclear fissions,targeted drugs,and Ki67 index are correlated with the prognosis of GOST,and immunohistochemical pro-teins have significant advantages in the diagnosis,estimation and treatment of GIST,which is beneficial to improve the prognosis of patients.
Stromal tumors of the gastrointestinal tractImmunohistochemistryClinical featuresPrognosis
万方数据
维普
